TrialCardiovascular diabetology2026

The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial.

Camilla Fuchs Andersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.